Bayer is expanding into molecular imaging through the definitive agreements to acquire AT-01 and AT-05, two investigational molecular imaging agents for the diagnosis of cardiac amyloidosis, from U.S.-based biotech company Attralus, Inc. The move marks Bayer’s entry into diagnostic tracers and reinforces its strategy to expand in the fast-growing field of molecular imaging.
The announcement was made by the companies on January 12, 2026, in Berlin, Germany, and Naples, Florida, according to a company press release. Financial terms of the transaction were not disclosed.
“With this strategic acquisition and the integration of novel molecular tracers into our development portfolio, we are advancing Bayer’s innovation strategy,” said Stefan Oelrich, Member of the Board of Management of Bayer AG and President of Bayer’s Pharmaceuticals Division. “AT-01 and AT-05 are precisely engineered to detect cardiac amyloidosis with high accuracy, enabling timely intervention and improved patient outcomes – a clear extension of our commitment to tackling cardiovascular disease and addressing significant unmet needs.”
Late-Stage PET and Early-Stage SPECT Tracers
The acquired assets include AT-01 (124-Iodine-evuzamitide), a pan-amyloid PET tracer currently in Phase III, and AT-05, a SPECT tracer in Phase I development. Both are designed to enable earlier and more accurate diagnosis of systemic and cardiac amyloidosis, conditions that are frequently underdiagnosed despite affecting an estimated 400,000 people globally.
AT-01 is notable as the first pan-amyloid imaging agent to receive U.S. FDA Breakthrough Therapy Designation for cardiac amyloidosis and also holds orphan drug designation in both the U.S. and EU.
Strengthening Precision Cardiology Ambitions
“With new therapies emerging for often insufficiently treated conditions such as cardiac amyloidosis, it becomes increasingly relevant to precisely detect and monitor diseases on the molecular level,” said Nelson Ambrogio, President Radiology at Bayer. “This acquisition marks our entry into diagnostic tracers.” Bayer said the transaction builds on its existing strengths in radiology, including advanced fluid delivery devices for nuclear medicine, and supports its broader shift toward precision cardiology.
Attralus Refocuses on Therapeutics
“We are excited to finalize this agreement with Bayer, whose expertise and global footprint in radiology will help to accelerate the development and launch of AT-01 and AT-05, our two novel diagnostic imaging agents for systemic amyloidosis,” said Glen Firestone, President of Attralus. Following the transaction, Attralus will focus on advancing its pan-amyloid removal therapeutics, including AT-02 in Phase II.
Source: Bayer
